electroCore Regains Compliance with Nasdaq Listing Requirements
07 Março 2023 - 10:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced that it has received
notice from the Listing Qualifications Department of the Nasdaq
Stock Market LLC (Nasdaq) by letter dated March 6, 2023 informing
electroCore that it has regained compliance with the minimum bid
price requirement under Nasdaq Listing Rule 5550(a)(2). The closing
bid price of the Company’s common stock on the Nasdaq Capital
Market was greater than $1.00 per share for 10 consecutive trading
days between February 15, 2023 and March 1, 2023. As a result of
regaining compliance, the Company’s common stock will continue to
be listed on the Nasdaq Capital Market.
About electroCore,
Inc.electroCore, Inc. is a commercial stage bioelectronic
medicine and wellness company dedicated to improving health through
its non-invasive vagus nerve stimulation (“nVNS”) technology
platform. Our focus is the commercialization of medical devices for
the management and treatment of certain medical conditions and
consumer product offerings utilizing nVNS to promote general
wellbeing and human performance in the United States and select
overseas markets.For more information, visit
www.electrocore.com.
Forward-Looking StatementsThis
press release and other written and oral statements made by
representatives of electroCore may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements about electroCore’s business
prospects and clinical and product development plans; its pipeline
or potential markets for its technologies; the timing, outcome and
impact of regulatory, clinical and commercial developments;
business prospects around its wellness and human performance
offerings and other new products and markets, its listing on the
Nasdaq Capital Market, and other statements that are not historical
in nature, particularly those that utilize terminology such as
"anticipates," "will," "expects," "believes," "intends," and other
words of similar meaning, derivations of such words and the use of
future dates. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to raise the additional
funding needed to continue to pursue electroCore’s business and
product development plans, the inherent uncertainties associated
with developing new products or technologies, the ability to
commercialize gammaCore™, TAC-STIM™, and Truvaga™, the potential
impact and effects of COVID-19 on the business of electroCore,
electroCore’s results of operations and financial performance,
inflation and currency fluctuations, and any measures electroCore
has and may take in response to COVID-19 and any expectations
electroCore may have with respect thereto, competition in the
industry in which electroCore operates and overall economic and
market conditions. Any forward-looking statements are made as of
the date of this press release, and electroCore assumes no
obligation to update the forward-looking statements or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
Investors should consult all of the information set forth herein
and should also refer to the risk factor disclosure set forth in
the reports and other documents electroCore files with the SEC
available at www.sec.gov.
Investors:Rich
CockrellCG Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024